Cristal Therapeutics raises additional funding for its lead product CriPec® docetaxel
Maastricht, The Netherlands, July 1, 2013 – Cristal Therapeutics, the new trade name of the Dutch nanomedicine company Cristal Delivery B.V., announces the successful expansion of the financing round initiated by Thuja Capital and BioGeneration Ventures, by adding two additional investors, being Nedermaas Ventures and Innovatie Fonds Limburg. The proceeds of this round will allow Cristal […]